Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Low Dose Fludarabine Is an Effective Conditioning Treatment to Suppress Relapse Rate in PT-CY-Based Haploidentical Peripheral Blood Stem Cell Transplantation

Jeong-A Kim, Jinhang Kim, Nanyoung Yun, Misuk Yang, Youngeun Jung

Blood (2024) 144 (Supplement 1): 510.

https://doi.org/10.1182/blood-2024-209588

Published: 2024

Journal Articles

Tumor-Primed CD3 + CD56 + natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Ji Hyun Lee, Seok-Ho Kim, Junsang Doh, Duck Cho, Jeong-a Kim, Sung Yong Oh, Sung-Hyun Kim, Juheon Lee

Blood (2024) 144 (Supplement 1): 2057.

https://doi.org/10.1182/blood-2024-200559

Published: 2024

Journal Articles

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Songyi Park, Sang-A Kim, Ji Yun Lee, Ja Min Byun, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Junglim Lee, Soo-Mee Bang, Inho Kim, Sung-Soo Yoon, Dongyeop Shin

Blood (2024) 144 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2024-202293

Published: 2024

Journal Articles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 3101.

https://doi.org/10.1182/blood-2024-194158

Published: 2024

Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2024-200914

Published: 2024

Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2024-200836

Published: 2024

Journal Articles

Real-World Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis at a Single Center

Sang-A Kim, Ji Yun Lee, Soo-Mee Bang, Jeong-Ok Lee

Blood (2023) 142 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2023-188410

Published: 2023

Journal Articles

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Jun Ho Yi, Seok Jin Kim, Sang A Kim, Jongheon Jung, Dok Hyun Yoon

Blood (2023) 142 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2023-186554

Published: 2023

Journal Articles

Coexpression of Tim-3 and PD-1 of T Lymphocytes Prevents Acute Graft-Versus-Host Disease

Jeong-A Kim, Jinhang Kim, Saetbyeol Kim, Misuk Yang

Blood (2023) 142 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2023-190640

Published: 2023

Journal Articles

Poverty and relapse risk in children with acute lymphoblastic leukemia: a Children’s Oncology Group study AALL03N1 report

Aman Wadhwa, Yanjun Chen, Lindsey Hageman, Anna Hoppmann, Anne Angiolillo, David S. Dickens, Joseph P. Neglia, Yaddanapudi Ravindranath, A. Kim Ritchey, Amanda Termuhlen, F. Lennie Wong, Wendy Landier, Smita Bhatia

Blood (2023) 142 (3): 221–229.

https://doi.org/10.1182/blood.2023019631

Published: 2023

Includes: Supplemental data

Journal Articles

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Ji Yun Lee, Soo-Mee Bang, Sang-A Kim, Youngil Koh, Ho-Young Yhim, Lee Gyeong-Won, Chang-Ki Min, Young Rok Do, Hyo Jung Kim, Sung Hwa Bae, Hyeon-Seok Eom, Je-Jung Lee, Hyunkyung Park, Seung-Hyun Nam, Ji Hyun Lee, Sung-Hyun Kim, Hyun Jung Lee, Min Kyoung Kim

Blood (2022) 140 (Supplement 1): 12501–12502.

https://doi.org/10.1182/blood-2022-165807

Published: 2022

Journal Articles

Preliminary Result of a Pilot Study of Apixaban in the Treatment of Splanchnic Vein Thrombosis

Sang-A Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang

Blood (2022) 140 (Supplement 1): 5678–5679.

https://doi.org/10.1182/blood-2022-168446

Published: 2022

Journal Articles

Incidence of Skeletal-Related Events Among Multiple Myeloma Patients: A Nationwide Population-Based Cohort Study

Ji Yun Lee, Ju Hyun Lee, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong-Seok Lee, Soo-Mee Bang, Eun Hee Jung, Minsu Kang

Blood (2022) 140 (Supplement 1): 12570.

https://doi.org/10.1182/blood-2022-168747

Published: 2022

Journal Articles

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Chang-Hoon Lee, Ga-Young Song, Jae-Yong Kwak, Deok-Hwan Yang

Blood (2022) 140 (Supplement 1): 6719–6720.

https://doi.org/10.1182/blood-2022-159929

Published: 2022

Journal Articles

Ex Vivo Culture with Albumin Greatly Increases the Immunosuppressive Subset of T Lymphocytes

Jeong-A Kim, Jinhang Kim, Saetbyeol Kim, Misuk Yang, Youngrok Park, Jae-Yong Kwak

Blood (2022) 140 (Supplement 1): 4538–4539.

https://doi.org/10.1182/blood-2022-163010

Published: 2022

Journal Articles

Ex Vivo IL-2 Treatment Increases the Immunosuppressive Subset of T Lymphocytes to Suppress Allo-Immune Response

Jeong-A Kim, Jinhang KIM, Misuk Yang, Youngrok Park, Jae-Yong Kwak

Blood (2021) 138 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2021-152462

Published: 2021

Journal Articles

A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sang A Kim, Youngil Koh, Miyoung Jung, Yu Kyeong Hwang, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon

Blood (2021) 138 (Supplement 1): 3835.

https://doi.org/10.1182/blood-2021-152137

Published: 2021

Journal Articles

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Blood (2021) 137 (16): 2161–2170.

https://doi.org/10.1182/blood.2020009004

Published: 2021

Includes: Supplemental data

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

NARROW

Low Dose Fludarabine Is an Effective Conditioning Treatment to Suppress Relapse Rate in PT-CY-Based Haploidentical Peripheral Blood Stem Cell Transplantation

Tumor-Primed CD3 + CD56 + natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Real-World Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis at a Single Center

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Coexpression of Tim-3 and PD-1 of T Lymphocytes Prevents Acute Graft-Versus-Host Disease

Poverty and relapse risk in children with acute lymphoblastic leukemia: a Children’s Oncology Group study AALL03N1 report

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Preliminary Result of a Pilot Study of Apixaban in the Treatment of Splanchnic Vein Thrombosis

Incidence of Skeletal-Related Events Among Multiple Myeloma Patients: A Nationwide Population-Based Cohort Study

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Ex Vivo Culture with Albumin Greatly Increases the Immunosuppressive Subset of T Lymphocytes

Ex Vivo IL-2 Treatment Increases the Immunosuppressive Subset of T Lymphocytes to Suppress Allo-Immune Response

A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only